Anticoagulant 'as good as warfarin' in VTE prevention

Dabigatran is as safe and effective as warfarin for preventing recurrent venous thromboembolism (VTE), without the need to monitor blood coagulation, data show.

Blood clots can be prevented effectively using dabigatran
Blood clots can be prevented effectively using dabigatran

The direct thrombin inhibitor, which is taken orally, is currently licensed for primary prevention of VTE after hip or knee surgery. Earlier this year data showed that it was safer and more effective than warfarin at preventing stroke in patients with AF (GP, 4 September).

Patients treated with dabigatran, which does not interact with foods and is not thought to have any drug interactions, do not need their coagulation levels monitored studies have shown.

For the latest study, Dr Sam Schulman of Karolinska University Hospital, Stockholm, and colleagues compared dabigatran with warfarin in 2,539 patients with acute VTE.

Patients were initially treated with parenteral anticoagulation. They were then given either warfarin, titrated to achieve an international normalised ratio of 2.0-3.0, or twice-daily dabigatran 150mg.

In total, 57 patients experienced recurrent, symptomatic and objectively confirmed VTE.

The proportion of patients who experienced these events did not differ significantly across the two treatment groups.

The safety profile of the two drugs was similar, although bleeding episodes occurred less frequently in patients given dabigatran.

Commenting on the latest findings, the researchers said: 'Our trial provides data to support dabigatran as a fixed-dose oral treatment for acute deep-vein thrombosis and pulmonary embolism.

'For patients and healthcare providers, dabigatran is a far more convenient drug than warfarin because it has no known interactions with foods and minimal interactions with other drugs.'

However, the researchers stressed that the drug was tested on a restricted sample of patients who were predominately white.

Additional studies will need to be performed in patients whose baseline characteristics differ markedly from this population, they said.

In addition, they pointed out that dabigatran was only given after initial parenteral anticoagulation therapy. There are therefore no data yet to support the use of dabigatran monotherapy for VTE, they said.

  • N Engl J Med 2009; 361: 2342-52

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Just published

GP on phone in recorded consultation assessment

Consultation skills to help GP trainees pass the RCA

Dr Afsar Rizvi highlights the key skills GP trainees need to master in order to pass...

Wes Streeting

Labour promises same GP 'each appointment' and face-to-face access if patients want it

A Labour government would offer patients the chance to see 'the same doctor each...

Man wearing mask on train

UK faces serious threat from flu and COVID-19 'twindemic' this winter

There are strong indications the UK faces a dangerous 'twindemic' of COVID-19 and...

NHS sign outside a building

PCN contract overhaul defers two-week appointment target until April 2023

NHS England has announced changes to the network contract DES, including deferring...

Coins

NHS sets out priorities for extra GP funding this winter

Integrated care boards could target extra funding for general practice at phone systems,...

Shadow chancellor Rachel Reeves

Labour promises to double medical school places with tax cut reversal

A Labour government would double medical school places with funding raised from reversing...